Almac Clinical Services, part of the Almac Group, has launched Almac Adapt, Just in Time Manufacturing (JTM) solution. This latest offering is designed to put patients first and provide sponsors with an adaptive supply strategy to meet the expanding challenges of clinical trials.
 
The drive to optimize the performance of clinical trials is increasing. Positive advancements, like the growth in development of targeted biopharmaceutical therapies and new trial designs, have had an impact on clinical development but have also brought new challenges to overcome. These challenges have resulted in aggressive study timelines, rising costs, the need for supply chain flexibility and the necessity to supply smaller, yet more global, clinical studies for specifically targeted populations.
 
The Almac Adapt solution offers the generation and delivery of kits to sites and patients worldwide in a matter of days, avoiding delays and over-production of sponsor’s drug product. When necessary, Almac Adapt can be coupled with Almac’s supply chain experts. According to the company, this solution manipulates the global supply chain and bridges the gap between supply and demand, optimizing on-time delivery for patients, inventory flexibility for sites while achieving key time-based milestones for the sponsor.
 
“The introduction of Almac Adapt further enhances Almac’s industry-leading capabilities within clinical trial supply showcasing our commitment to advancing human health,” said Natalie Balanovsky, manager, Just in Time Manufacturing (JTM) Solutions, Almac Clinical Services. “We understand the challenges our clients are facing at a deeper level and we have the resource, experience and expertise to help by developing a robust Just in Time strategy. Working directly with sponsors we will deliver a flexible, adaptable and patient–centric supply solution. Because time is precious to both sponsors and patients nothing is more important to us than ensuring we deliver on this promise. I am delighted to announce the launch of Almac Adapt.”